Does Utah Medicaid cover Wegovy and Zepbound in 2026?
Not for new patients. As of Oct 23, 2026, Utah Medicaid is closed to new starts of GLP-1 drugs for obesity alone.
Closed to new starts Checked Oct 23, 2026 Pilot ended Jun 30, 2026
Coverage of GLP-1 drugs for obesity alone under Utah’s fee-for-service Medicaid drug rules, as the state publishes them. The plan decides each request.
Utah’s rule
In plain words
Closed to new starts
A legislative pilot ran from Jul 1, 2025 to Jun 30, 2026 for fee-for-service members; new starts for obesity alone are closed.
The Jun 1, 2026 form lets people approved for weight loss between Jul 1, 2025 and Jun 30, 2026 ask for renewal, and warns that coverage may not continue past Jun 30, 2026. It does not say what happens after that date.
Source
Utah Medicaid PA form, GLP-1 Medications for Weight-related Comorbidities, updated 6-1-26 (opens in new tab). Checked Oct 23, 2026.
Federal Medicaid law lets a state exclude these drugs only “when used for anorexia, weight loss, or weight gain”; their use for type 2 diabetes is not on that list, though a state may require prior authorization. Social Security Act §1927(d)(1)(A) and (d)(2)(A), 42 U.S.C. 1396r-8(d) (opens in new tab).
What changed
- Jun 30, 2026: Utah’s legislative pilot for weight-loss GLP-1s (fee-for-service) reached its end date; the form allows renewals only. Utah Medicaid PA form, updated 6-1-26 (opens in new tab)
Next steps
Where to go from here
Neighbouring states
Questions this page answers
Does Utah Medicaid cover Wegovy and Zepbound for weight loss?
Not for new patients. As of Oct 23, 2026, Utah Medicaid is closed to new starts of GLP-1 drugs for obesity alone. A legislative pilot ran from Jul 1, 2025 to Jun 30, 2026 for fee-for-service members; new starts for obesity alone are closed.
Has Utah’s rule changed recently?
Jun 30, 2026: Utah’s legislative pilot for weight-loss GLP-1s (fee-for-service) reached its end date; the form allows renewals only.
Where does this information come from?
From Utah Medicaid PA form, GLP-1 Medications for Weight-related Comorbidities, updated 6-1-26, read on Oct 23, 2026. Federal Medicaid law lets a state exclude these drugs only “when used for anorexia, weight loss, or weight gain”; their use for type 2 diabetes is not on that list, though a state may require prior authorization.
Kymata Health reads each state’s own Medicaid documents. See every state on the map.